MINIPRESS

This brand name is authorized in Australia, Brazil, Estonia, Spain, Japan, Lithuania, United States

Active ingredients

The drug MINIPRESS contains one active pharmaceutical ingredient (API):

1 Prazosin UNII X0Z7454B90 - PRAZOSIN HYDROCHLORIDE

Prazosin causes a decrease in total peripheral vascular resistance through selective inhibition of postsynaptic alpha-1-adrenoreceptors in vascular smooth muscle. Prazosin has been found to successfully reduce the severity of the signs, symptoms, frequency and duration of attacks, in patients with Raynaud’s disease. Read about Prazosin

Medication package inserts

Below package inserts are available for further reading:

Title	Information Source	Document Type
MINIPRESS Capsule	FDA, National Drug Code (US)	MPI, US: SPL/Old

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
C02CA01	Prazosin	C Cardiovascular system → C02 Antihypertensives → C02C Antiadrenergic agents, peripherally acting → C02CA Alpha-adrenoreceptor antagonists
Discover more medicines within C02CA01

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: AU	Pharmaceutical Benefits Scheme	Identifier(s): 1478T, 1479W, 1480X
Country: BR	Câmara de Regulação do Mercado de Medicamentos	Identifier(s): 522717120068207, 522717120068307, 522717120068407
Country: EE	Ravimiamet	Identifier(s): 1022768, 1136607, 1172517, 1782312, 1782389, 1789702, 1799174, 1816635
Country: ES	Centro de información online de medicamentos de la AEMPS	Identifier(s): 55062, 55063, 55064
Country: JP	医薬品医療機器総合機構	Identifier(s): 2149002F1128, 2149002F2159
Country: LT	Valstybinė vaistų kontrolės tarnyba	Identifier(s): 1090658
Country: US	FDA, National Drug Code	Identifier(s): 0069-4310, 0069-4370, 0069-4380